Асосий контентга ўтиш
AkademIndex

Хизматлар

← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

152 та иш

Иш: Microbiome Oncolytic Virus Interactions in Cancer: Emerging Evidence and Therapeutic Implications for Immunotherapy

  1. Tumor Cell-Targeting and Tumor Microenvironment–Responsive Nanoplatforms for the Multimodal Imaging-Guided Photodynamic/Photothermal/Chemodynamic Treatment of Cervical Cancer

    Ying Wang, Yiyan Xu, Jiayu Song +8

    Мақола202411 иқтибос
    ABI

  2. A <scp>TGF</scp>‐β signaling‐related <scp>lncRNA</scp> signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Weiwei Duan, Liting Yang, Jian Liu +13

    Мақола20238 иқтибос
    ABI

  3. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

    Vancheswaran Gopalakrishnan, C. N. Spencer, Luigi Nezi +67

    Мақола20177 иқтибос
    ABI

  4. An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination

    Hanqi Zhang, Buzi Cao, Qingtai Cao +3

    Шарҳ мақола20235 иқтибос
    ABI

  5. Oncolytic virotherapy

    Stephen J. Russell, Kah-Whye Peng, John C. Bell

    Шарҳ мақола20124 иқтибос
    ABI

  6. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

    Khalil Khalaf, Doris Hana, Jadzia Tin-Tsen Chou +3

    Шарҳ мақола20214 иқтибос
    ABI

  7. Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure

    Xiaorong Ma, Hong Cheng, Junwei Hou +6

    Мақола20204 иқтибос
    ABI

  8. Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy

    Ayelet Sivan, Leticia Corrales, Nathaniel Hubert +9

    Мақола20154 иқтибос
    ABI

  9. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

    Vyara Matson, Jessica Fessler, Riyue Bao +5

    Мақола20184 иқтибос
    ABI

  10. The human tumor microbiome is composed of tumor type–specific intracellular bacteria

    Deborah Nejman, Ilana Livyatan, Garold Fuks +58

    Мақола20204 иқтибос
    ABI

  11. Sweet syndrome induced by SARS-CoV-2 vaccines: A systematic review of patient-report studies

    Yilai Jia, Boyang Fu, Liping Dong +1

    Шарҳ мақола20234 иқтибос
    ABI

  12. Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma

    Han Gong, Zhaolong Liu, Chunhui Yuan +8

    Мақола20244 иқтибос
    ABI

  13. Сарлавҳасиз

    Бошқа4 иқтибос
    ABI

  14. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

    Takeshi Tanoue, Satoru Morita, Damian R. Plichta +25

    Мақола20193 иқтибос
    ABI

  15. Oncolytic viruses: challenges and considerations in an evolving clinical landscape

    Ulrich M. Lauer, Julia Beil

    Шарҳ мақола20223 иқтибос
    ABI

  16. Сарлавҳасиз

    Бошқа3 иқтибос
    ABI

  17. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota

    Danfeng Chen, Duochen Jin, Shumin Huang +12

    Мақола20193 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа3 иқтибос
    ABI

  19. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

    Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas +40

    Мақола20223 иқтибос
    ABI

  20. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

    Leore T. Geller, Michal Barzily-Rokni, Tal Danino +44

    Мақола20173 иқтибос
    ABI

  21. Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8+ T cell infiltration

    Shuo Wang, Lingkai Kong, Linpei Wang +7

    Мақола20253 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа3 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа2 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа2 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа2 иқтибос
    ABI